1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Omeros Corporation

Omeros Corporation

OMER
Omeros CorporationUS flagNASDAQ Global Market
20.13
USD
-0.61
- -
1.46BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.02
0.36
1.03
1.42
0.61
- -
- -
- -
- -
- -
- -
- -
0.55
Basic EPS, GAAP
-1.39
-2.22
-2
-1.65
-1.17
-2.61
-1.71
-2.41
3.12
0.76
-1.88
-2.7
-0.05
1.78
Free Cash Flow per Basic Share
-1.05
-1.75
-1.74
-1.28
-0.8
-2.15
-1.22
-1.76
-1.76
-1.38
1.18
-2.56
-1.83
-0.98
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.61
-1.25
-0.69
-0.85
-0.06
-2.04
-2.01
-1.96
0.38
1.36
-0.41
-3.15
-1.69
-0.71
Tangible Book Value per Share
-0.61
-1.25
-0.69
-0.85
-0.06
-2.04
-2.01
-1.96
0.38
1.36
-0.41
-3.15
-1.69
-0.71
Basic Weighted Avg Shares
29
33
38
40
46
49
50
57
62
63
63
58
64
70
Sales/Revenue/Turnover
2
1
14
42
65
30
- -
- -
- -
- -
- -
- -
- -
38
Operating Margin (%)
-3,157.25
-12,988.5
-527.34
-130.42
-67.71
-375.73
- -
- -
- -
- -
- -
- -
- -
-189.53
Depreciation Expense
- -
- -
- -
- -
1
1
2
2
1
1
1
1
1
1
Net Income, GAAP
-40
-74
-75
-67
-53
-127
-84
-138
194
47
-118
-157
-3
125
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.07
Profit Margin (%)
-2,487.25
-13,668.46
-555.9
-160.38
-82.5
-424.39
- -
- -
- -
- -
- -
- -
- -
324.88
Working Capital
3
-9
21
44
82
53
48
115
196
307
165
55
138
90
LT Debt
15
26
50
80
84
151
191
265
343
243
231
180
216
101
Total Equity
-18
-43
-26
-37
-3
-100
-109
-121
24
86
-25
-183
-121
-51
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-331.18
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
638.95
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
86.63
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
23
6
38
LT Borrowings
209
137
97
LT Finance Leases
7
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
72
Market Capitalization
1,231
760
686

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
216
180
185
Cash, Cash Equivalents & STI
172
135
132
Accounts Receivable, Net
6
12
18
Inventories
- -
- -
1
Total Current Liabilities
78
59
95
Payables & Accruals
21
21
19
ST Debt
23
6
38
Deferred Revenue
2
3
5

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
403.78%
121.76%
-33.61%
Free Cash Flow
-36.11%
-104%
-22.02%
Net Income, GAAP
-59.34%
-145.9%
-97.86%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
10
29
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.63
-0.97
-0.56
-0.54
-2.7
2025
-0.58
-0.43
-0.47
1.22
-0.05
2026
0.78
0.18
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gregory A. Demopulos
Full Time Employees
175
Sector
Healthcare
Industry
Biotechnology
Address
The Omeros Building Seattle WA United States of America 98119
IPO Date
Oct 8, 2009
CIK
0001285819
Website
omeros.com
Similar Companies
Cassava Sciences, Inc. (SAVA)
BetterLife Pharma Inc. (BETRF)
Molecular Partners AG (MOLN.SW)
Medicus Pharma Ltd. Common Stock (MDCXW)
Alps Group Inc (ALPS)
Nanoform Finland Oyj (NANOFH.HE)
Business
Omeros Corporation Omeros Corporation (Nasdaq: OMER), founded in 1994 and headquartered in Seattle, Washington, operates as a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, addictive and compulsive disorders, and central nervous system conditions; its approved product OMIDRIA (phenylephrine and ketorolac intraocular solution 1%/0.3%) maintains pupil size and reduces postoperative pain in patients undergoing cataract surgery or intraocular lens replacement; lead pipeline candidates include the MASP-2 inhibitor narsoplimab (OMS721) under FDA review for hematopoietic stem cell transplant-associated thrombotic microangiopathy, the long-acting MASP-2 inhibitor OMS1029 in Phase 1, small-molecule inhibitors of MASP-2, MASP-3 and MASP-2/3, the PDE7 inhibitor OMS527 in clinical development for cocaine use disorder funded by the National Institute on Drug Abuse, PPAR gamma (PPARγ) agonists such as OMS405 for addiction disorders including opioids, nicotine and alcohol, GPR174 inhibitors and cellular therapies enhancing T-cell function for immuno-oncology applications, and other programs leveraging its proprietary GPCR platform for orphan and large-market indications with operations primarily in the United States. In recent developments, Omeros entered a definitive agreement in October 2025 with Novo Nordisk for the asset purchase and license of its clinical-stage MASP-3 inhibitor zaltenibart (OMS906) targeting paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy, providing up to $2.1 billion in upfront, milestone and royalty payments while retaining rights to certain preclinical MASP-3 programs; the company also announced agreements in May 2025 to acquire $80.5 million of its convertible senior notes due 2026 and convert an additional $10 million into common stock to strengthen its balance sheet ahead of potential narsoplimab commercialization.

Company News

Company News APIChatGPT

  • defenseworld.net

    Omeros (NASDAQ:OMER) Hits New 1-Year High – Should You Buy?

  • benzinga.com

    Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

  • defenseworld.net

    Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND)

  • defenseworld.net

    BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER

  • zacks.com

    What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

  • zacks.com

    Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

  • defenseworld.net

    Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

  • seekingalpha.com

    Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    Omeros Q2 Earnings Call Highlights

  • zacks.com

    Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

  • businesswire.com

    Omeros Corporation Reports Second Quarter 2026 Financial Results

  • businesswire.com

    Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

  • defenseworld.net

    Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

  • businesswire.com

    CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER